Novozymes Biopharma, part of Novozymes, has announced the first shipment of the company's Bacillus-derived hyaluronic acid, Hyasis, from its newly inaugurated manufacturing facility in China, which represents an investment of more than DKK 350 million.

The facility in Tianjin employs a patented water-based process to manufacture Hyasis to Q7 cGMP standards.

The first commercial products using Hyasis as a raw material are expected to reach the market in Q2 of this year.